Suzhou, China – BIOCHINA2024, a premier event in the biotechnology and pharmaceutical industries, successfully concluded with a record-breaking 27,931 registrants, 480 exhibitors, and 839 speakers from around the world. This year's event, held in Suzhou, highlighted cutting-edge advancements in drug licensing, supply chain optimization, product promotion, and funding access within the biotech sector.

Looking ahead, BIOCHINA 2025 has officially announced its next conference, set for March 13-15, 2025. The 10th edition of the event covering 50,000 square meters across five halls. Exhibitors will showcase a wide range of products and services, including pharmaceutical equipment, laboratory instruments, technical services, and raw materials, as well as reagents and consumables. International exhibitors will also be a key highlight.

BIOCHINA 2025 will associate with top-tier Chinese biotech and biopharmaceutical companies, covering key areas such as cell and gene therapy, antibody drugs, vaccines, small molecule drugs, peptide drugs, and nucleic acid drugs. This focus on advanced biotechnologies positions BIOCHINA 2025 as a central hub for innovation and collaboration in the industry.